Reuters logo
BRIEF-Adamis Pharmaceuticals announces NDA resubmission of its allergy treatment drug
December 16, 2016 / 2:20 PM / 9 months ago

BRIEF-Adamis Pharmaceuticals announces NDA resubmission of its allergy treatment drug

Dec 16 (Reuters) - Adamis Pharmaceuticals Corp -

* Resubmission is intended to address issues raised by FDA in agency’s June 2016 complete response letter

* Adamis Pharmaceuticals announces NDA resubmission of its epinephrine pre-filled syringe application to the FDA Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below